对动脉样硬化斑块的有效向 - 活体优化PLGA纳米颗粒
L Martín-Navarro1, M D Herrera2, J Álvarez-Fuentes3
1Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González 2, Sevilla 41012, Spain.
Colloids and surfaces. B, Biointerfaces
|August 26, 2025
概括
这项研究开发了向纳米颗粒,用于输送CB2受体激动剂以减少动脉样硬化. 这种新系统有效地将大麻素输送到斑块部位,显著减少小鼠的炎症和斑块形成.
科学领域:
- 纳米医学
- 药理学
- 心血管研究
背景情况:
- 有选择性的CB2受体激动剂显示出治疗动脉样硬化的潜力.
- 这些激动剂的不良物理化学特性阻碍了临床应用.
- 需要有针对性的交付系统来克服这些局限性.
研究的目的:
- 设计一种基于纳米粒子的输送系统,
- 通过向VCAM-1,这是动脉样硬化病变的生物标志物来功能化纳米颗粒.
- 在体外和体内评估这种向输送系统的有效性.
主要方法:
- 使用PLGA,PLGA-PEG和PLGA-PEG-Mal聚合物的混合物合成PEG化PLGA纳米粒子 (NP).
- 通过maleimide-click反应将与NP结合.
- 使用人类血管内皮细胞进行的体外评估和在ApoE-/-小鼠体内研究.
主要成果:
- 通过1:1的maleimide-to-ligand摩尔比率实现了最佳的NP功能化.
- 在体外,功能化的NP降低了炎症标志物,并恢复了内皮细胞的氧化平衡.
- 在活体中,NP 显示了对动脉的特定部位的传递,显著减少了动脉硬化斑块的形成.
结论:
- 开发的纳米系统是针对大麻素的有希望的策略.
- 这种方法为开发抗动脉增生疗法提供了新的途径.
- 有针对性的输送系统可以促进动脉样硬化的治疗.
相关概念视频
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Atherosclerosis I: Introduction
77
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
77
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645


